Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Your Impact
    • How You Can Help
    • Events

Funded Grants

Back to results

A Randomized Controlled Trial of Pimozide in Subjects with ALS

Project Overview

This project is a Phase II study involving 100 participants across 8 ALS clinics across Canada. The trial, led by the Principal Investigator of the Canadian Neuromuscular Disease Registry (CNDR) and the Chair of the Canadian ALS Research Network (CALS) will examine whether pimozide, a drug already approved by Health Canada for use in psychoses like schizophrenia and Tourette’s syndrome, might slow progression of ALS. Pimozide is particularly effective at stabilizing neuromuscular function, which means it can strengthen the connection where the motor neuron meets the muscle (called the neuromuscular junction or NMJ). It is hoped that by strengthening this connection, there will be preservation of transmission of signals from the brain to the muscle and slowing of paralysis in ALS. The project also involves the validation of an exciting new potential biomarker. Biomarkers are ways of monitoring the body (eg. looking for something in blood or doing a particular physical examination) to either diagnose ALS earlier, select individuals for a trial or monitor effectiveness of a treatment.

 

Principal Investigator

Lawrence Korngut , University of Calgary

Partners and Donors

ALS Society of Canada

Project Ongoing

A Randomized Controlled Trial of Pimozide in Subjects with ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Arthur J. Hudson Translational Team Grant

  • Province

    Alberta

  • Start Date

    2016

  • Total Grant Amount

    $489,856

  • Health Canada Contribution

    $244,928

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign up

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co